加拿大的非專利藥品市場：形成市場的趨勢及主要企業

Abstract

Overview

Introduction

The Canadian pharmaceutical market is the 8th largest globally and as such represents an important market for generics manufacturers. Although historically dominated by domestic generics companies, mergers and acquisitions over the last five years have increased the dominance of foreign players.

Scope

• Overview of the size of the Canadian generics market
• Review of the leading drug classes driving generic sales growth
• Assessment of the key drivers and resistors affecting the Canadian generics market
• Profiles of the leading companies in the Canadian generics market

Report Highlights

The Canadian generics sector has grown more rapidly than the pharmaceutical market as a whole over recent years. However, this growth has not been driven by significant volume increases or price rises, instead it has been a number of recent launches of new generics of high selling brands that have altered the product mix.

Domestic generics manufacturers have historically had an advantage in this market however overseas players have increased there presence through acquisitions over recent years to enable them to benefit from the same advantages.

Reasons to Purchase

• Assess the size of the Canadian generics market and the key therapeutic classes that are driving growth
• Examine the growth drivers and resistors that are shaping this significant generics market
• Benchmark the key companies operating in the Canadian generics market

Table of Contents

• CHAPTER 1 EXECUTIVE SUMMARY
  • Scope of the report
  • Key findings
• CHAPTER 2 OVERVIEW OF THE CANADIAN GENERICS MARKET
  • Scope
  • Introduction to the Canadian pharmaceutical market
    • Canada' s pharmaceutical market has experienced double-digit prescription sales growth since 2002
    • The generics market represents a significant proportion of both prescription volume and total market value
  • Key issues affecting the Canadian generics market
    • The establishment of the Canadian generics market
    • Differences in healthcare environment and cost-containment initiatives between provinces increase the complexity of operating in the Canadian generics market
    • Key drivers and resistors impacting the Canadian Generics Market
    • A range of resistors impact generic market growth
      • Market exclusivity extension: generics companies must wait longer for generic entry
      • Pseudo-generics: inhibiting ' real' generic growth
    • A number of drivers are helping to drive generics market growth in Canada
      • Compulsory licensing for export to developing countries: theoretically an opportunity for generic growth, but in practice proving complex
      • High cost of generic drugs in Canada relative to rest of world favors generic manufacturers
      • Early working exception policy accelerating speed to market for generic drugs in Canada
      • Biosimilars - a potential new industry
• CHAPTER 3 KEY GENERICS COMPANIES OPERATING IN THE CANADIAN MARKET
  • Introduction
  • Apotex - the largest Canadian-owned generics manufacturer in Canada
    • Overview
    • Company strategy
      • Speed to market
      • Patent challenges
      • Diversification into biosimilars
      • Access to niche markets via Cangene
      • Diversification into proprietary drugs
      • Apotex' s domestic position
    • Company outlook
  • Teva
    • Overview
    • Company strategy
      • First to file patent challenges
      • Good distribution infrastructure in Canada
      • Proprietary drug development
      • Expansion into biosimilar market
    • Company outlook
  • Merck KGaA (Merck Serono)
    • Overview
    • Company strategy
      • Growing pipeline
      • Diversification into more specialist areas
      • Geographic growth by M&A
    • Company outlook
  • ratiopharm
    • Overview
    • Company strategy
      • Geographical expansion
      • Expansion into controlled release delivery market
      • Expansion into biosimilar market
  • Pharmascience - the second largest Canadian-owned generics manufacturer
    • Overview
    • Company strategy
      • Pipeline expansion
      • Manufacturing facilities
      • International ventures
      • Diversification into OTC business
    • Company outlook
  • Other generic pharmaceutical companies
    • Cobalt Pharma
    • Stiefel Laboratories
    • Axcan Pharma
    • Mayne Pharma
    • Ranbaxy
    • Taro Pharmaceuticals
    • Sandoz (Novartis)
• CHAPTER 4 BIBLIOGRAPHY
  • List of Tables
    • Table 1: Estimates of Canadian market size, 2003 and 2005
    • Table 2: Comparison of drug sales per capita
  • List of Figures
    • Figure 1: Ethical sales in Canada 2003-05: $5 billion increase in prescription sales
    • Figure 2: Total market sales and generic sector sales 2002-05
    • Figure 3: The generic market share as a percentage of total pharmaceutical sales varies across markets
    • Figure 4: Key issues in Canadian generic industry, 2007
    • Figure 5: Purpose of launching pseudo-generics/licensed generics globally